• +1-646-491-9876
    • +91-20-67278686

    Search

    Tinea pedis Pipeline Review H1 2017

    Tinea pedis Pipeline Review H1 2017

    • Report Code ID: RW0001858654
    • Category Pharmaceuticals
    • No. of Pages 44
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017, provides an overview of the Tinea pedis (Athlete Foot) (Infectious Disease) pipeline landscape.

    Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tinea pedis (Athlete Foot) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical, Discovery and Unknown stages are 1, 5, 2, 1 and 1 respectively.

    Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Tinea pedis (Athlete Foot) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Tinea pedis (Athlete Foot) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tinea pedis (Athlete Foot) - Overview
    Tinea pedis (Athlete Foot) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Tinea pedis (Athlete Foot) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tinea pedis (Athlete Foot) - Companies Involved in Therapeutics Development
    Astellas Pharma Inc
    Biolab Farmaceutica Ltda
    Blueberry Therapeutics Ltd
    Dermala Inc
    Helix BioMedix Inc
    Novan Inc
    Sol-Gel Technologies Ltd
    Viamet Pharmaceuticals Inc
    Tinea pedis (Athlete Foot) - Drug Profiles
    AS-2077715 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dapaconazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Athlete's Foot - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    E-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HB-1275 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nitric oxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SB-208 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    terbinafine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    terbinafine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VT-1161 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tinea pedis (Athlete Foot) - Dormant Projects
    Tinea pedis (Athlete Foot) - Product Development Milestones
    Featured News & Press Releases
    Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
    Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
    Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
    Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis
    Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Tinea pedis (Athlete Foot) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Tinea pedis (Athlete Foot) - Pipeline by Astellas Pharma Inc, H1 2017
    Tinea pedis (Athlete Foot) - Pipeline by Biolab Farmaceutica Ltda, H1 2017
    Tinea pedis (Athlete Foot) - Pipeline by Blueberry Therapeutics Ltd, H1 2017
    Tinea pedis (Athlete Foot) - Pipeline by Dermala Inc, H1 2017
    Tinea pedis (Athlete Foot) - Pipeline by Helix BioMedix Inc, H1 2017
    Tinea pedis (Athlete Foot) - Pipeline by Novan Inc, H1 2017
    Tinea pedis (Athlete Foot) - Pipeline by Sol-Gel Technologies Ltd, H1 2017
    Tinea pedis (Athlete Foot) - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
    Tinea pedis (Athlete Foot) - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Tinea pedis (Athlete Foot) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Astellas Pharma Inc
    Biolab Farmaceutica Ltda
    Blueberry Therapeutics Ltd
    Dermala Inc
    Helix BioMedix Inc
    Novan Inc
    Sol-Gel Technologies Ltd
    Viamet Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//tinea-pedis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//tinea-pedis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//tinea-pedis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments